Skip to content

Sufentanil on Anesthesia Introduction and Recovery Quality in Pediatric Adenotonsillectomy

Effect of Three Doses of Sufentanil on Anesthesia Introduction and Recovery Quality in Pediatric Adenotonsillectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04067648
Acronym
SFTA
Enrollment
90
Registered
2019-08-26
Start date
2020-07-06
Completion date
2022-12-18
Last updated
2023-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sufentanil

Keywords

Sufentanil, perfusion index

Brief summary

To study the effect of different doses of sufentanil on anesthesia induction and analgesia after tonsillectomy in children. According to the different doses of sufentanil used in anesthesia induction, the children were divided into 3groups. The vital signs during anesthesia, the recovery period of anesthesia and the complications after anesthesia were compared among the groups. The anesthetic effects and safety of sufentanil at different doses were discussed, which provided theoretical basis for clinical selection of the best drug dosage.

Detailed description

Fifteen minutes before operation, midazolam 0.1 mg/kg was slowly intravenously injected. Five minutes later, the child entered the operating room. Pi, Narcotrend, blood pressure, ECG, SpO2 and body temperature were monitored. Penehyclidine hydrochloride 0.01 mg/kg, dexamethasone 0.1 mg/kg, propofol 3 mg/kg, sufentanil (0.3μg/kg, 0.4 μg/kg, 0.5 μg/kg) were given during anesthesia induction. cis-atracurium 0.15 mg/kg, using the required type of tube for tracheal intubation. Sevoflurane 1.0 MAC + remifentanil 0.15 ug/kg/min 50% oxygen was given during anesthesia maintenance. Effective analgesia was achieved by adjusting the dosage of remifentanil during operation. The changes of vital signs including perfusion index, Narcotrend, Bp, HR, oxygen saturation were observed before anesthesia induction, immediately after tracheal intubation, during tonsillectomy and adenoidectomy during operation, after extubation and in the recovery room. Then record the recovery time, restlessness and pain score during recovery period, postoperative pain, nausea and vomiting and other complications.

Interventions

three doses of sufentanil was intravenously given during anesthesia induction

Sponsors

Tongji Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Masking description

Observers and patients were double-blind. Sufentanil was assigned by a specialist. Different doses of sufentanil were allocated in the same volume according to the weight of the child.

Eligibility

Sex/Gender
ALL
Age
1 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* Age 1-12 years, * ASA I-II grade; * selective adenotonsillectomy * BMI 18.5~23.9, * Sign informed consent

Exclusion criteria

* Emergency surgery; * Abnormal liver and kidney function * severe dehydration and malnutrition or Hb \< 10g/dl; * BMI \<18.5 or \<23.9; * Children with neurological disorders

Design outcomes

Primary

MeasureTime frameDescription
adequate sufentanil dose24 hoursAdequate sufentanil dose is determined by Optimal intubation conditions and No hypotension or other severe side effects

Secondary

MeasureTime frameDescription
cut off value of Pi for valid stress assessment24 hoursa validated and useful stress assessment for children during endotracheal intubation.
Narcotrend index24 hoursexplore dose and age-related hemodynamic effects of sufentanil. Next to blood pressure and heart rate and continuous Narcotrend will be monitored. Then record the correlation between perfusion index and Narcotrend
postoperative complications with different doses of sufentanil7daysIncluding postoperative pain and the dosage of analgesics after operation and the satisfaction of children and parents

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026